Ginkgo Bioworks went public two years ago via a special purpose acquisition company. Deep losses and significant cash burn have made investors wary of investing in this risky stock. Special purpose ...

BOSTON, April 11, 2024 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, is hosting its 5th annual Ferment conference.

Two former leaders from Boston-based Ginkgo Bioworks are among those behind Ferment, a newly capitalized venture studio that aims to create “bio-enabled” product companies. Ginkgo Bioworks food ...

BOSTON, Feb. 6, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the 2025 Ferment Series, an evolution of ...

Ginkgo Bioworks (NYSE: DNA) went public a few years ago. With sky-high expectations for growth spanning multiple industries, it may have been tempting for investors to take a chance on the ...

Ferment will begin with a keynote address from Ginkgo co-founder and CEO, Jason Kelly, who will discuss the value that customers across industries can create on Ginkgo's platform, whether they're ...